Cadila Healthcare receives US FDA approval for schizophrenia drug
The product will be manufactured at Liva Pharma's manufacturing facility at Vadodara
Cadila Healthcare | US FDA | Schizophrenia
Drug firm Cadila Healthcare on Thursday said it has received approval from the USFDA for Haloperidol Decanoate injection used in treatment of schizophrenia.
The product will be manufactured at Liva Pharma's manufacturing facility at Vadodara, Cadila Healthcare said in a BSE filing.
Haloperidol is used in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
First Published: Thu, October 24 2019. 11:40 IST